Christopher David Taves Sells 176,786 Shares of MediPharm Labs (TSE:LABS) Stock

MediPharm Labs Corp. (TSE:LABS) Director Christopher David Taves sold 176,786 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of C$0.08, for a total transaction of C$14,142.88. Following the completion of the sale, the director owned 2,847,939 shares of the company’s stock, valued at approximately C$227,835.12. This trade represents a 5.84% decrease in their position.

MediPharm Labs Stock Up 7.1%

LABS stock opened at C$0.08 on Friday. The company has a fifty day moving average price of C$0.08 and a 200 day moving average price of C$0.07. MediPharm Labs Corp. has a 12 month low of C$0.06 and a 12 month high of C$0.10. The company has a market cap of C$31.86 million, a price-to-earnings ratio of -3.75 and a beta of -0.61. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.02 and a quick ratio of 3.10.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products produced in a GMP-certified facility with ISO-standard clean rooms. MediPharm has invested in an expert research-driven team, state-of-the-art technology, advanced purification methodologies, and purpose-built facilities to deliver pure, trusted, precision-dosed cannabinoid products for domestic and international markets.